Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02477332 · ClinicalTrials.gov registry record · Phase 2
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 382
- Enrollment target
NCT02477332 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 382 participants.
The verdict
NCT02477332, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 382 participants
- Enrollment target
Study Summary
This is a placebo and active-controlled phase 2b dose-finding study to evaluate efficacy and safety of QGE031 monthly subcutaneous injections as add-on therapy in patients with Chronic Spontaneous Urticaria.
Interventions
- OTHER Placebo
- BIOLOGICAL Omalizumab
- BIOLOGICAL QGE031
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 382 participants |
| Start Date | 2015-07-15 |
| Est. Completion | 2017-06-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02477332
The ClinicalTrials.gov registry entry for NCT02477332 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 382 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02477332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02477332 about?
NCT02477332 is a clinical study titled "Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU". This is a placebo and active-controlled phase 2b dose-finding study to evaluate efficacy and safety of QGE031 monthly subcutaneous injections as add-on therapy in patients with Chronic Spontaneous Urticaria.
What is the current status of trial NCT02477332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 382 participants. The study started on 2015-07-15. Estimated completion is 2017-06-12.
What interventions are being tested in trial NCT02477332?
The interventions under investigation include: Placebo (OTHER), Omalizumab (BIOLOGICAL), QGE031 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02477332?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.